SG Americas Securities LLC Takes $393,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

SG Americas Securities LLC bought a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the third quarter, HoldingsChannel reports. The fund bought 45,187 shares of the biopharmaceutical company’s stock, valued at approximately $393,000.

A number of other institutional investors also recently bought and sold shares of the stock. Amalgamated Bank raised its holdings in Ocular Therapeutix by 37.9% in the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,481 shares during the period. Ameritas Investment Partners Inc. raised its holdings in Ocular Therapeutix by 39.4% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,531 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 3,257 shares during the period. Victory Capital Management Inc. raised its holdings in Ocular Therapeutix by 36.9% in the 2nd quarter. Victory Capital Management Inc. now owns 17,403 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 4,695 shares during the period. Atlas Capital Advisors LLC bought a new position in Ocular Therapeutix in the 2nd quarter worth $34,000. Finally, Essex Investment Management Co. LLC raised its holdings in Ocular Therapeutix by 1.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 376,200 shares of the biopharmaceutical company’s stock worth $3,423,000 after purchasing an additional 5,828 shares during the period. 59.21% of the stock is owned by institutional investors.

Analyst Ratings Changes

OCUL has been the topic of a number of recent research reports. TD Cowen cut Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a report on Friday, June 21st. Scotiabank assumed coverage on Ocular Therapeutix in a research note on Wednesday. They issued a “sector outperform” rating and a $22.00 price target for the company. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Friday, June 21st. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Ocular Therapeutix in a research note on Wednesday. Finally, Robert W. Baird cut their price target on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Ocular Therapeutix Trading Down 3.3 %

Shares of Ocular Therapeutix stock opened at $11.09 on Friday. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -8.21 and a beta of 1.29. The business has a 50-day moving average price of $8.96 and a 200-day moving average price of $7.44. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18. Ocular Therapeutix, Inc. has a twelve month low of $2.00 and a twelve month high of $11.58.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). The firm had revenue of $16.40 million for the quarter, compared to analysts’ expectations of $15.85 million. Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The company’s revenue for the quarter was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.27) EPS. Equities research analysts anticipate that Ocular Therapeutix, Inc. will post -1.02 EPS for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.